Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aMILs +/- Vaccine in Multiple Myeloma
NCT01045460Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2010
- Primary completion
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
A Phase 2 trial of marrow-infiltrating lymphocytes, allogeneic myeloma vaccine in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2010; status: completed.
02
Drugs
marrow-infiltrating lymphocytesallogeneic myeloma vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01045460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01045460.